Cell Kinetics OCF Margin
Delisted
The Operating Cash Flow Margin of Cell Kinetics (CKNTF) as of Jul 16, 2026 is -11,350.00 %.
Get this data via API
Financial Data API
OCF Margin
-11,350.00 %
Last updated:
Operating Cash Flow Margin of Cell Kinetics is 2026 -11,350.00 % . Operating Cash Flow Margin of Cell Kinetics was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Cell Kinetics Stock analysis
What does Cell Kinetics do? Cell Kinetics Ltd is a company specializing in the research and production of cell therapy products. The company was founded in 2020 and is based in London, United Kingdom.
Cell Kinetics Ltd has a visionary mission that inspires the company to discover and develop groundbreaking solutions to improve people's health and well-being. The company aims to research, develop, and deliver therapies for serious diseases such as cancer and neurodegenerative disorders.
The business model of Cell Kinetics Ltd is based on comprehensive research of new cell therapies and collaboration with academic partners to validate the clinical benefits of these therapies. The company has established partnerships with leading academic institutions and medical centers in Europe and the USA.
Cell Kinetics Ltd works in various areas to achieve the goal of discovering and developing new therapies for serious diseases. An important focus of the company is the development of cell culture methods for the production and maintenance of therapeutic cells in large quantities. The company has extensive experience in developing artificial platforms for cell cultivation, including bioreactor-based cultivation, single-cell-sensitive cultivation, and the use of chemicals for cell cultivation.
Another focus of Cell Kinetics Ltd is the development of carcinoma therapies. The company has developed a special technology for the production of T-cells that can be used to kill cancer cells. These T-cells are obtained from blood samples of cancer patients and cultivated in vitro. The company has also developed a technology that allows these T-cells to be modified to fight deadly diseases such as leukemia and lymphoma.
Another focus of Cell Kinetics Ltd is the development of therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company is developing special technologies to differentiate neural stem cells that can serve as a therapeutic tool for the treatment of these diseases. These neural stem cells can be used to repair damaged nerve cells.
Cell Kinetics Ltd is proud to offer a range of products that can contribute to improving the health and well-being of patients. The company offers therapy products for cancer treatment, neurodegenerative diseases, and cardiovascular diseases, among others. In addition, the company also provides a wide range of services, including the development and production of cell therapy products, as well as artificial platforms for cell cultivation.
Overall, Cell Kinetics Ltd has become a major player in the field of cell therapy and the development of therapies for serious diseases. The company is committed to continuing to develop groundbreaking discoveries and technologies to improve the lives of millions of people around the world. Cell Kinetics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Cell Kinetics stock
Operating Cash Flow Margin of Cell Kinetics is -11,350.00 % in 2026.
Access this data via the Eulerpool API
Margins — Cell Kinetics
All Key Metrics — Cell Kinetics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth